Toripalimab (JS001 )

DRUG2 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd.

Conditions

Hepatocellular CarcinomaUrothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma RecurrentUrothelial Carcinoma of the Renal Pelvis and Ureter

Phase 1

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

TerminatedNCT03867370

Shanghai Junshi Bioscience Co., Ltd.Hepatocellular Carcinoma

Start: 2019-04-26End: 2023-08-08Updated: 2023-11-29

Phase 2

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

RecruitingNCT06823427

Mabwell (Shanghai) Bioscience Co., Ltd.Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter +1

Start: 2025-01-17End: 2027-06-30Target: 60Updated: 2025-03-21

Related Papers

Abstract 486: A phase Ib/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC)

Cancer Research2021-07-0119 citations